Prognostic Significance of Serum Proangiogenic Molecules in Patients with De Novo Non-Hodgkin Lymphomas

Table 1

Initial characteristics of 79 patients with de novo NHL.

Characteristic	No (%)
Performance status (ECOG ≥2)	15 (19.0)
B symptoms	46 (58.2)
Ann Arbor stage
I	7 (8.9)
II	22 (27.8)
III	10 (12.7)
IV	40 (50.6)
Bulky disease	28 (35.4)
Bone marrow involvement	26 (32.9)
High serum LDH	46 (58.2)
Histological subtype
Diffuse large cell lymphoma	54 (68.4)
Follicular lymphoma	8 (10.1)
Mantle cell lymphoma	3 (3.8)
Lymphoblastic lymphoma	2 (2.5)
Burkitt’s lymphoma	1 (1.3)
Mucosa-associated lymphoid tissue	1 (1.3)
Peripheral T-cell lymphoma, unclassified	6 (7.6)
Anaplastic large cell lymphoma	3 (3.8)
Angioimmunoblastic T-cell lymphoma	1 (1.3)
International prognostic index
Low risk	24 (30.4)
Low-intermediate risk	20 (25.3)
High-intermediate risk	21 (26.6)
High risk	14 (17.7)
Chemotherapy
CHOP	44 (55.7)
R-CHOP	22 (27.8)
Other	7 (8.9)
No chemotherapy	6 (7.6)